Nilesh Kumar Sharma

Prof. Dr. Nilesh Kumar Sharma

Biotechnology, Dr. D. Y. Patil Biotechnology and Bioinformatics Institute, Pune, India

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2011 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
ARAurelio Reyes
Aurelio Reyes
PGPaula Green
Paula Green
MCMatthieu J. Caron
Matthieu J. Caron
MBMarcelo G. Bonini
Marcelo G. Bonini
JSJanine Hertzog Santos
Janine Hertzog Santos
Human telomerase reverse transcriptase (hTERT) is localized to mitochondria, as well as the nucleus, but details about its biology and function in the organelle remain largely unknown. Here we show, using multiple approaches, that mammalian TERT is mitochondrial, co-purifying with mitochondrial nucleoids and tRNAs. We demonstrate the canonical nuclear RNA [human telomerase RNA (hTR)] is not present in human mitochondria and not required for the mitochondrial effects of telomerase, which nevertheless rely on reverse transcriptase (RT) activity. Using RNA immunoprecipitations from whole cell and in organello , we show that hTERT binds various mitochondrial RNAs, suggesting that RT activity in the organelle is reconstituted with mitochondrial RNAs. In support of this conclusion, TERT drives first strand cDNA synthesis in vitro in the absence of hTR. Finally, we demonstrate that absence of hTERT specifically in mitochondria with maintenance of its nuclear function negatively impacts the organelle. Our data indicate that mitochondrial hTERT works as a hTR-independent reverse transcriptase, and highlight that nuclear and mitochondrial telomerases have different cellular functions. The implications of these findings to both the mitochondrial and telomerase fields are discussed.

19 July 2018 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
PNPritish Nilendu
Pritish Nilendu
SSSachin Sarode
Sachin Sarode
DJDevashree Jahagirdar
Devashree Jahagirdar
ITIshita Tandon
Ishita Tandon
SPShankargouda Patil
Shankargouda Patil
NSNilesh Kumar Sharma
Nilesh Kumar Sharma

1 January 2014 in DNA Repair
Verified
Journal Article
Closed access
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
MLMaria Lebedeva
Maria Lebedeva
TTTerace Thomas
Terace Thomas
OKOlga A. Kovalenko
Olga A. Kovalenko
JSJeffrey D. Stumpf
Jeffrey D. Stumpf
Janine SantosJanine Santos
Janine Santos

8 December 2017 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
HPHimadri Patel
Himadri Patel
PNPritish Nilendu
Pritish Nilendu
DJDevashree Jahagirdar
Devashree Jahagirdar
JPJayanta K Pal
Jayanta K Pal
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
The microenvironment in which cancer resides plays an important role in regulating cancer survival, progression, malignancy and drug resistance. Tumor microenvironment (TME) consists of heterogeneous number and types of cellular and non-cellular components that vary in relation to tumor phenotype and genotype. In recent, non-cellular secreted components of microenvironmental heterogeneity have been suggested to contain various growth factors, cytokines, RNA, DNA, metabolites, structural matrix and matricellular proteins. These non-cellular components have been indicated to orchestrate numerous ways to support cancer survival and progression by providing metabolites, energy, growth signals, evading immune surveillance, drug resistance environment, metastatic and angiogenesis cues. Thus, switching action from pro-cancer to anti-cancer activities of these secreted components of TME has been considered as a new avenue in cancer therapeutics and drug resistance. In this report, we summarize the recent pre-clinical and clinical evidences to emphasize the importance of non-cellular components of TME in achieving precision therapeutics and biomarker study.

6 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
ABAnjali Bahot
Anjali Bahot
GSGopinath Sekar
Gopinath Sekar
MBMahima Bansode
Mahima Bansode
KKKratika Khunteta
Kratika Khunteta
Birandra K. K SinhaBirandra K. K Sinha
Birandra K. K Sinha
In recent years, the emergence of cancer drug resistance has been one of the crucial tumor hallmarks that are supported by the level of genetic heterogeneity and complexities at cellular levels. Oxidative stress, immune evasion, metabolic reprogramming, overexpression of ABC transporters, and stemness are among the several key contributing molecular and cellular response mechanisms. Topo-active drugs, e.g., doxorubicin and topotecan, are clinically active and are utilized extensively against a wide variety of human tumors and often result in the development of resistance and failure to therapy. Thus, there is an urgent need for an incremental and comprehensive understanding of mechanisms of cancer drug resistance specifically in the context of topo-active drugs. This review delves into the intricate mechanistic aspects of these intracellular and extracellular topo-active drug resistance mechanisms and explores the use of potential combinatorial approaches by utilizing various topo-active drugs and inhibitors of pathways involved in drug resistance. We believe that this review will help guide basic scientists, pre-clinicians, clinicians, and policymakers toward holistic and interdisciplinary strategies that transcend resistance, renewing optimism in the ongoing battle against cancer.

7 April 2020 in Future Oncology
Verified
Journal Article
Closed access
SRSayantani Roychoudhury
Sayantani Roychoudhury
AKAjay Kumar
Ajay Kumar
DBDevyani Bhatkar
Devyani Bhatkar
NSNilesh Kumar Sharma
Nilesh Kumar Sharma
In recent, intra- and inter-tumor heterogeneity is seen as one of key factors behind success and failure of chemotherapy. Incessant use of doxorubicin (DOX) drug is associated with numerous post-tr...